← Home

During treatment

Symptom monitoring during anticancer therapy

Symptoms can emerge between scheduled visits during systemic treatment. A research system may help the team see a structured signal, but it must not provide autonomous treatment decisions to the patient.

Audience
For oncology clinics and research teams
Status
Research information, not medical advice
Editorial
NPO NT project team; scientific concept by Dr Artem Poltoratskiy
Review
No independent external medical review of this edition is claimed
Updated
Reviewed 19 August 2026
01

What to monitor

The symptom set depends on the regimen, population and research question. A universal questionnaire without a clinical owner can increase burden without improving safety.

  • Symptoms and functional impact using a suitable instrument.
  • Treatment-cycle context and prespecified events.
  • The minimum necessary passive measures.
  • Contact, review and action by the authorised team.
02

Why a backup route matters

Participants must know when not to wait for a digital response. Hours, expected response time, clinic contact and emergency instructions are communicated before monitoring starts. This public website is not a care channel.

03

Outcomes for a pilot

  • Completion and device-wear rates.
  • Time from signal to review.
  • Signals requiring action.
  • Patient and staff burden.
  • Prespecified care-use or quality-of-life outcomes only when the design supports them.